18 Mar 2014

Azarga (Brinzolamide / Timololo) - Italia

ATC: S01ED
SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
BETA BLOCKING AGENTS
Azarga

Last Updated on 18 Mar 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Azarga Indication

Riduzione della pressione intraoculare (PIO) in pazienti adulti con glaucoma ad angolo aperto o ipertensione oculare per i quali la monoterapia produce una riduzione della PIO insufficiente.

Azarga Generic Name

Brinzolamide / Timololo

Type

POM

Summary Product Characteristics (SPCs) Links
Riassunto delle Caratteristiche del Prodotto - Azarga (external site)

Related Learning Zones

Symptomatic Asthma Knowledge Centre

Symptomatic Asthma Knowledge Centre

Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Learning Zone, consisting of a Disease Awareness section, is free to access for all epgonline.org members, and has been designed to provide them with the information they need to effectively manage the symptoms of their patients with asthma.

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Related Information

Azarga Marketing Information

Azarga Generic Name
Brinzolamide / Timololo
Marketing Company
Alcon Laboratories (UK) Ltd.
Drug Type
POM
Date of Issue, Marketing Authority

25/11/2008

Related Drugs - Eye Health and Disorders

Back to top